290 related articles for article (PubMed ID: 19296472)
21. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
Markovina S; Callander NS; O'Connor SL; Kim J; Werndli JE; Raschko M; Leith CP; Kahl BS; Kim K; Miyamoto S
Mol Cancer Res; 2008 Aug; 6(8):1356-64. PubMed ID: 18708367
[TBL] [Abstract][Full Text] [Related]
23. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
Stessman HA; Lulla A; Xia T; Mitra A; Harding T; Mansoor A; Myers CL; Van Ness BG; Dolloff NG
Leukemia; 2014 Nov; 28(11):2263-7. PubMed ID: 25005244
[No Abstract] [Full Text] [Related]
24. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Chauhan D; Singh AV; Brahmandam M; Carrasco R; Bandi M; Hideshima T; Bianchi G; Podar K; Tai YT; Mitsiades C; Raje N; Jaye DL; Kumar SK; Richardson P; Munshi N; Anderson KC
Cancer Cell; 2009 Oct; 16(4):309-23. PubMed ID: 19800576
[TBL] [Abstract][Full Text] [Related]
25. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Jones MD; Liu JC; Barthel TK; Hussain S; Lovria E; Cheng D; Schoonmaker JA; Mulay S; Ayers DC; Bouxsein ML; Stein GS; Mukherjee S; Lian JB
Clin Cancer Res; 2010 Oct; 16(20):4978-89. PubMed ID: 20843837
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
Shabaneh TB; Downey SL; Goddard AL; Screen M; Lucas MM; Eastman A; Kisselev AF
PLoS One; 2013; 8(2):e56132. PubMed ID: 23460792
[TBL] [Abstract][Full Text] [Related]
29. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Chauhan D; Singh A; Brahmandam M; Podar K; Hideshima T; Richardson P; Munshi N; Palladino MA; Anderson KC
Blood; 2008 Feb; 111(3):1654-64. PubMed ID: 18006697
[TBL] [Abstract][Full Text] [Related]
30. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
31. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
[TBL] [Abstract][Full Text] [Related]
32. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
[TBL] [Abstract][Full Text] [Related]
33. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
34. High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma.
Zhou Y; Goodenbour JM; Godley LA; Wickrema A; Pan T
Biochem Biophys Res Commun; 2009 Jul; 385(2):160-4. PubMed ID: 19450555
[TBL] [Abstract][Full Text] [Related]
35. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Gutman D; Morales AA; Boise LH
Leukemia; 2009 Nov; 23(11):2181-3. PubMed ID: 19516276
[No Abstract] [Full Text] [Related]
36. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
[TBL] [Abstract][Full Text] [Related]
38. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
39. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
40. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
